Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
Author: Jillian Dabney
According to top-line results of Novo Nordisk's Leader trial, Victoza proved to be superior to existing treatments in reducing cardiovascular risks in patients with type two diabetes.
Global big pharmaceutical companies that have major exposure to Europe will be impacted significantly by Brexit. The depreciating euro will impact sales.
Analysts expected Valeant to record $2.5 billion and $2.6 billion in total revenue during 3Q16 and 4Q16. The yearly revenue will fall 9.6% during 3Q16.
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn't meet its primary endpoint. Horizon stock fell 22.5% that day.
Considering the robust growth prospects for many of its products going forward, Pfizer should return to robust top line growth.
Mallinckrodt (MNK) has recently been making news due to its business model being questioned. A Citron Research report focused on the sustainability of Acthar’s higher level of exposure to government-oriented franchise.